Preclinical studies demonstrate that BTLA blockade restores T cell effector function, increases IFN-γ production, and enhances tumor control in melanoma, colon, and hepatocellular carcinoma models [5,17,68]. The gene discussed is BTLA; the disease is hepatocellular carcinoma.